首页> 外文期刊>Oncology letters >Efficacy analysis of trastuzumab, carboplatin and docetaxel in HER-2-positive breast cancer patients
【24h】

Efficacy analysis of trastuzumab, carboplatin and docetaxel in HER-2-positive breast cancer patients

机译:曲妥珠单抗,卡铂和多西紫杉醇在Her-2阳性乳腺癌患者中的疗效分析

获取原文
获取原文并翻译 | 示例
           

摘要

Efficacy of trastuzumab, carboplatin and docetaxel in human epidermal growth factor receptor-2 (HER-2)-positive breast cancer patients was investigated. A total of 180 HER-2-positive breast cancer patients admitted to The First People's Hospital of Yunnan Province were selected, of which 80 patients were treated with carboplatin and docetaxel and served as the control group (CG), and 100 patients were treated with trastuzumab, carboplatin and docetaxel and served as the research group (RG). Clinical efficacy, pathological efficacy, adverse reactions, inflammatory factors interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), cellular immune indexes of T-lymphocyte subsets (CD4(+), CD8(+), CD4(+)/CD8(+)), and the oxidative stress indexes superoxide dismutase (SOD) and myeloperoxidase (MPO) were observed before and after treatment and were compared between both groups. Patients were followed up for 5 years, and the 5-year disease-free survival (DFS), as well as the overall survival (OS) were compared. Clinical efficacy and pathological efficacy in the RG were significantly higher than those in the CG, and the incidence rate of adverse reactions had no significant difference between the two groups. There was no significant difference in inflammatory factors, cellular immune indexes and oxidative stress indexes between the two groups before treatment. After treatment, the levels of IL-6, TNF-alpha, CD8(+) and MPO in both groups were significantly reduced and were significantly lower in RG than those in CG. However, the levels of CD4(+), CD4(+)/CD8(+) and SOD in both groups were significantly increased after treatment and were significantly higher in RG than those in CG. The 5-year DFS and OS of the RG were significantly higher than those of the CG. In conclusion, trastuzumab, carboplatin and docetaxel present high efficacy, safety, and 5-year DFS and OS in HER-2-positive breast cancer patients, and have good recovery effect on inflammation, immune response and oxidative stress.
机译:研究了曲妥珠单抗,卡铂和多西紫杉醇在人表皮生长因子受体-2(HER-2) - 阳性乳腺癌患者中的疗效进行了研究。选择了180名她的280名阳性乳腺癌患者,录取了云南省第一人民医院,其中80名患者用卡铂和多西紫杉醇治疗,并作为对照组(CG),100名患者被治疗Trastuzumab,Carboplatin和Docetaxel,并作为研究组(RG)。临床疗效,病理疗效,不良反应,炎症因子白细胞介素-6(IL-6)和肿瘤坏死因子 - α(TNF-α),T淋巴细胞亚群的细胞免疫指标(CD4(+),CD8(+),在治疗之前和之后观察到CD4(+)/ CD8(+))和氧化应激指数超氧化物歧化酶(SOD)和髓过氧化物酶(MPO),并在两个基团之间进行比较。患者随访5年,比较了5年的无病生存(DFS),以及整体存活率(OS)。 RG中的临床疗效和病理效果显着高于CG中的疗效,不良反应的发生率在两组之间没有显着差异。在治疗前两组之间的炎性因子,细胞免疫指标和氧化应激指数没有显着差异。治疗后,两组IL-6,TNF-α,CD8(+)和MPO的水平显着降低,RG显着降低了CG中的含量。然而,治疗后,两组中的CD4(+),CD4(+)/ CD8(+)和SOD的水平显着增加,并且Rg明显高于CG中的含量。 RG的5年DFS和OS显着高于CG。总之,曲妥珠单抗,卡铂和多西紫杉醇在她 - 2阳性乳腺癌患者中具有高疗效,安全和5年的DFS和OS,对炎症,免疫应答和氧化应激具有良好的恢复效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号